Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages

Oncolytic viruses (OVs) for cancer treatment are in a rapid stage of development, and the direct tumor lysis and activation of a comprehensive host immune response are irreplaceable advantages of cancer immunotherapy. However, excessive antiviral immune responses also restrict the spread of OVs in v...

Full description

Saved in:
Bibliographic Details
Published in:Journal of translational medicine 2023-11, Vol.21 (1), p.842-842, Article 842
Main Authors: Shen, Zhen, Liu, Xiyu, Fan, Guixiang, Na, Jintong, Liu, Qiaoqiao, Lin, Faquan, Zhang, Zhikun, Zhong, Liping
Format: Article
Language:English
Subjects:
Analysis
Angiogenesis
Antigen (tumor-associated)
Antigen presentation
Antiviral agents
Cancer immunotherapy
Cancer therapies
Care and treatment
Chemokines
Cytokines
Diagnosis
Dosage and administration
Drug resistance
Functional plasticity
Genotype & phenotype
Growth factors
Humans
Immune response
Immune system
Immunotherapy
Innate immunity
Lymphocytes
Lysis
Macrophage
Macrophage reprogramming
Macrophages
Macrophages - pathology
Neoplasms
Oncolysis
Oncolytic Virotherapy
Oncolytic virus
Oncolytic Viruses
Pathogens
Tumor cells
Tumor necrosis factor-TNF
Tumors
Virotherapy
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oncolytic viruses (OVs) for cancer treatment are in a rapid stage of development, and the direct tumor lysis and activation of a comprehensive host immune response are irreplaceable advantages of cancer immunotherapy. However, excessive antiviral immune responses also restrict the spread of OVs in vivo and the infection of tumor cells. Macrophages are functionally diverse innate immune cells that phagocytose tumor cells and present antigens to activate the immune response, while also limiting the delivery of OVs to tumors. Studies have shown that the functional propensity of macrophages between OVs and tumor cells affects the overall therapeutic effect of oncolytic virotherapy. How to effectively avoid the restrictive effect of macrophages on OVs and reshape the function of tumor-associated macrophages in oncolytic virotherapy is an important challenge we are now facing. Here, we review and summarize the complex dual role of macrophages in oncolytic virotherapy, highlighting how the functional characteristics of macrophage plasticity can be utilized to cooperate with OVs to enhance anti-tumor effects, as well as highlighting the importance of designing and optimizing delivery modalities for OVs in the future.
ISSN:1479-5876
1479-5876
DOI:10.1186/s12967-023-04709-z